论文部分内容阅读
Sorafenib is used worldwide as a first-line standard systemic agent for advanced hepatocellular carcinoma(HCC)on the basis of the results of two large-scale PhaseⅢtrials.Conversely,hepatic arterial infusion chemotherapy(HAIC)is one of the most recommended